Posters

Evaluation of the vascular changes in myopic choroidal neovascularization after intravitreal ranibizubam using optical coherence tomography angiography

Poster Details

First Author: G.Cennamo ITALY

Co Author(s):    F. Amoroso   M. Alfieri   G. de Crecchio                       

Abstract Details



Purpose:

Describe the optical coherence tomography angiography (OCT-A) characteristics of myopic patients with choroidal neovascularization secondary to pathologic myopia during the ranibizumab therapy.

Setting:

Clinical practice study

Methods:

this retrospective study included nineteen patients (13 females, 6 males, mean age 55.25 ± 9.63years), for a total of 20 eyes examined (14 right eyes, 6 left eyes). Images were analyzed by two different examiners.

Results:

Patients had a mean follow-up of 5.75 ± 1.88 months, with a mean IVT number of 1.90 ± 0.44. Mean BCVA at baseline was 0.39 ± 0.18LogMAR; after follow-up, it was 0.26 ± 0.16LogMAR. Both the BCVA (Z= -3.055, p=0.002) and the neovascular area (Z= -2.091, p=0.037) had a statistically significant reduction after treatment, contrary to the reduction of the vessel density, which was not significant (Z= -1.848, p=0.065). The neovascular areas were significantly correlated with the BCVA, both at baseline and at follow-up (p<0.05)

Conclusions:

Our data suggests that OCT-A is a reproducible and non-invasive examination, which provides a reliable follow-up over time as for the neovascular size area in pathologic myopia.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy